GENinCode Press Releases

Published on December 16, 2024 - 13:00 GMT

CARDIO inCode® publication in International Journal of Cardiology Cardiovascular Risk and Prevention

Individuals with a high polygenic risk are likely to derive the most benefit from lifestyle change and/or therapeutic intervention IRVINE, CA, UNITED STATES, December 16, 2024 /⁨EINPresswire.com⁩/ -- GENinCode U.S., the genetics company focused on the prevention of cardiovascular disease, announces the publication in the International Journal of Cardiology Cardiovascular Risk and Prevention of a clinical research study on the ‘Interplay between Lifestyle Factors and Polygenic Risk for Incident Coronary …

Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...
Published on September 20, 2024 - 12:45 GMT

DISCOVER FH collaboration with Family Heart Foundation®, UT Southwestern, and Partners

LIPID inCode®, tests patients to identify familial hypercholesterolemia and prevent cardiovascular disease OXFORD, UNITED KINGDOM, September 20, 2024 /⁨EINPresswire.com⁩/ -- GENinCode Plc (LSE AIM: GENI), the genetics company focused on the prevention of cardiovascular disease and ovarian cancer, announces its collaboration with The Family Heart Foundation®, UT Southwestern, and other partner members to use the LIPID inCode® monogenic and polygenic test in US Primary and Secondary Care settings for the …

Distribution channels: Banking, Finance & Investment Industry, Companies ...
Published on August 29, 2024 - 10:00 GMT

CARDIO inCode-Score presentation on polygenic risk of Coronary Heart Disease at the 2024 ESC Annual Congress, London

IRVINE, US, August 29, 2024 /⁨EINPresswire.com⁩/ -- GENinCode US Inc, the polygenics company focused on the prevention of cardiovascular disease and ovarian cancer, announces the presentation by Kaiser Permanente on the interplay between family history and polygenic risk on the incidence of coronary heart disease (“CHD”) which will take place at the 2024 Annual Congress of the European Society of Cardiology (“ESC”) in London from 30 August to 2 September 2024. Following the March 2024 milestone …

Distribution channels: Banking, Finance & Investment Industry, Companies ...

Contact

Matthew Walls
GENinCode
+1 949-930-0462

email us here

Share This Newsroom

Facebook Twitter LinkedIn

Company/Organization

GENinCode US Inc
5 Mason, Suite 200
Irvine, 92618
United States
+1 949-930-0462
Visit Website

Facebook X LinkedIn

About

GENinCode provide patients and physicians with globally leading risk assessment tools to inform cardiovascular preventive care and treatment. Our technologies combine monogenic, polygenic and clinical information to provide advanced patient risk assessment to predict and prevent cardiovascular disease.

http://www.genincode.com

The Newsroom of GENinCode US Inc

CARDIO inCode® publication in International Journal of Cardiology Cardiovascular Risk and Prevention

DISCOVER FH collaboration with Family Heart Foundation®, UT Southwestern, and Partners

CARDIO inCode-Score presentation on polygenic risk of Coronary Heart Disease at the 2024 ESC Annual Congress, London